AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY ACUTE MYELOID LEUKEMIA

by Gert J. Ossenkoppele, Jeroen J.W.M. Janssen, Peter C. Huijgens
Published 2013-02-01

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia

by Gert J. Ossenkoppele, Jeroen J.W.M. Janssen, Arjan A. van de Loosdrecht
Published 2016-01-01

Divergent Autologous T Cell Responses to Leukaemic Dendritic Cells during Remission in Acute Promyelocytic Leukaemia

by Theresia M. Westers, Ilse Houtenbos, Arjan A. van de Loosdrecht, Gert J. Ossenkoppele
Published 2005-01-01

Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?

by Tania Martiáñez Canales, David C. de Leeuw, Eline Vermue, Gert J. Ossenkoppele, Linda Smit
Published 2017-06-01

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML

by Diana Hanekamp, Jesse M. Tettero, Gert J. Ossenkoppele, Angèle Kelder, Jacqueline Cloos, Gerrit Jan Schuurhuis
Published 2021-05-01

MRD Tailored Therapy in AML: What We Have Learned So Far

by Lok Lam Ngai, Angèle Kelder, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos
Published 2021-01-01

Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells

by Jeroen J.W.M. Janssen, Fedor Denkers, Peter Valk, Jan J. Cornelissen, Gerrit-Jan Schuurhuis, Gert J. Ossenkoppele
Published 2010-06-01

The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?

by Margot F. van Spronsen, Theresia M. Westers, Birgit I. Lissenberg-Witte, Mariëlle Wondergem, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht
Published 2019-12-01

The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells

by Noortje van Gils, Tania Martiañez Canales, Eline Vermue, Arjo Rutten, Fedor Denkers, Tiem van der Deure, Gert J. Ossenkoppele, Francis Giles, Linda Smit
Published 2021-08-01

Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome

by Martine E.D. Chamuleau, Theresia M. Westers, Linda van Dreunen, Judith Groenland, Adri Zevenbergen, Corien M. Eeltink, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht
Published 2009-04-01

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

by Corine J. Hess, Nicole Feller, Fedor Denkers, Angèle Kelder, Pauline A. Merle, Michael C. Heinrich, Amy Harlow, Johannes Berkhof, Gert J. Ossenkoppele, Quinten Waisfisz, Gerrit J. Schuurhuis
Published 2009-01-01

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG

by Roland B. Walter, Megan Othus, Bob Löwenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christiane Vekemans, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey
Published 2015-10-01

Maturation State-Specific Alternative Splicing in <i>FLT3</i>-ITD and NPM1 Mutated AML

by Anna Wojtuszkiewicz, Inge van der Werf, Stephan Hutter, Wencke Walter, Constance Baer, Wolfgang Kern, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Claudia Haferlach, Jacqueline Cloos, Torsten Haferlach
Published 2021-08-01

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

by Monique Terwijn, Wendelien Zeijlemaker, Angèle Kelder, Arjo P Rutten, Alexander N Snel, Willemijn J Scholten, Thomas Pabst, Gregor Verhoef, Bob Löwenberg, Sonja Zweegman, Gert J Ossenkoppele, Gerrit J Schuurhuis
Published 2014-01-01

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

by Gerrit J Schuurhuis, Michael H Meel, Floris Wouters, Lisa A Min, Monique Terwijn, Nick A de Jonge, Angele Kelder, Alexander N Snel, Sonja Zweegman, Gert J Ossenkoppele, Linda Smit
Published 2013-01-01

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes

by Josephine D. Kahn, Martine E.D. Chamuleau, Theresa M. Westers, Peter M. Van de Ven, Linda van Dreunen, Margot van Spronsen, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht
Published 2015-06-01

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

by Jurjen M Ruben, Lindy L Visser, Kimberley M Heinhuis, Tom O'Toole, Hetty J Bontkes, Theresia M Westers, Gert J Ossenkoppele, Tanja D de Gruijl, Arjan A van de Loosdrecht
Published 2015-01-01

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

by Martine E.D. Chamuleau, Arjan A. van de Loosdrecht, Corine J. Hess, Jeroen J.W.M. Janssen, Adri Zevenbergen, Ruud Delwel, Peter J.M. Valk, Bob Löwenberg, Gert J. Ossenkoppele
Published 2008-12-01

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

by Marvin M. van Luijn, Martine E.D. Chamuleau, James A. Thompson, Suzanne Ostrand-Rosenberg, Theresia M. Westers, Yuri Souwer, Gert J. Ossenkoppele, S. Marieke van Ham, Arjan A. van de Loosdrecht
Published 2010-03-01

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

by Marvin M van Luijn, Arjan A van de Loosdrecht, Margit H Lampen, Peter A van Veelen, Adri Zevenbergen, Michel G D Kester, Arnoud H de Ru, Gert J Ossenkoppele, Thorbald van Hall, S Marieke van Ham
Published 2012-01-01